I-Therapeutix, Inc. Closes $15 Million Financing
...agement, more than 20 investment professionals, and current investments in more than 115 companies. Polaris-backed successes in life sciences include adnexus
(sold to Bristol-Myers Squibb), Advanced Inhalation Research (sold to Alkermes), Alnylam Pharmaceuticals (ALNY), Glycofi (sold to Merck), Momenta Phar...
Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007
...viously announced Productivity
Transformation Initiative, $230 million for acquired in-process research
and development relating to the acquisition of adnexus
and $275 million
relating to an impairment of the company's investment in certain auction
rate securities (ARS).
As of December 31, 2007, the compan...
Biotech Finishes on a High in August, Burrill Report Says
... midpoint of the proposed $14-$16 price
range. Its shares jumped 10.8% by the end of August. Eight companies added themselves to the IPO runway:
Therapeutics, which is focused on discovering, developing, and commercializing the proprietary drug class called Adnectins. Adnexus' first pr...
Bristol-Myers Squibb to Acquire Adnexus Therapeutics
Bristol-Myers Squibb to Advance Biologics Strategy Through Targeted Biologics Acquisition
PRINCETON, N.J. and WALTHAM, Mass., Sept. 24 /PRNewswire-FirstCall/ --
Bristol-Myers Squibb Company (NYSE: BMY ) and Adnexus(TM) Therapeutics
announced today the companies have ...
Accuri Cytometers Completes $4 Million Series D Financing
...leantech. During the past two decades Flagship's principals have been involved as founders or investors in many highly successful ventures including: adnexus
Therapeutics, Alere Medical, Aspect Medical, Celera Genomics, ChemGenics Pharmaceuticals, Color Kinetics, Cytyc, Helicos Biosciences, Hypnion, IDEXX, ...
Microbia, Inc. Names Alex Chu as Vice President of Process Development
...perience in bioprocess development and manufacturing to Microbia. He was most recently the vice president of manufacturing and process development at adnexus
Therapeutics, Bristol-Myers Squibb. Prior to this, he held multiple scientific and management positions at Abbott Laboratories and Abbott BioResearch ...
Accuri Cytometers Completes $13 Million Series C Financing
...Cleantech. During the past two decades
Flagship's principals have been involved as founders or investors in many
highly successful ventures including: adnexus
Therapeutics, Alere Medical,
Aspect Medical, Celera Genomics, ChemGenics Pharmaceuticals, Color
Kinetics, Cytyc, Helicos Biosciences, Hypnion, IDEXX, ...
Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team
...Irvine and his B.A. in Computer Science
and Biochemistry from the University of California, Los Angeles.
Dr. John Mendlein recently served as CEO of adnexus
developer of a new class of protein therapeutics) from May 2005 until
October 2007, at which time the privately-held, Boston based bio...
Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community
...n BioPharma company, Bristol-Myers Squibb seeks to
reallocate resources to enable additional strategic acquisitions, such as
the recent acquisition of adnexus
Therapeutics, as well as pursue
partnerships and other collaborative arrangements. These alliances should
add to the company's innovative capabilities...